Guided Therapeutics (Norcross, GA) has shipped four additional LuViva Advanced Cervical Scan systems—which scan the cervix with light and use spectroscopy to measure how light interacts with the cervical tissue to noninvasively diagnose cervical cancer—to Bangladesh for use in the country's cervical cancer screening program. This brings the total number of platforms shipped there to 12.
In Bangladesh, where cervical cancer is the leading cancer among women, the screening-age population is estimated to be 38 million.
The global market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.
The company has also shipped 1000 of its disposable Cervical Guides to date, which work with the LuViva system.
For more information, please visit www.guidedinc.com.
